This post has been archived and contains information that may be out of date.
The Food and Drug Administration (FDA) has authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients, and the Centers for Medicare & Medicaid Services (CMS) has created new billing codes for the treatment.
The emergency use authorization covers treatment of symptoms in patients when they have a positive COVID-19 test result, are at high-risk for progression to severe COVID-19, and alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them.
The new CMS billing codes for bebtelovimab include:
- Q0222
- Long descriptor: Injection, bebtelovimab, 175 mg
- Short descriptor: Bebtelovimab 175
- M0222
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring
- Short Descriptor: Bebtelovimab injection
- M0223
- Long Descriptor: Intravenous injection, bebtelovimab — includes injection and post-administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
- Short Descriptor: Bebtelovimab injection home
Additional information is available on the CMS COVID-19 Monoclonal Antibodies web page.
